Scarica l'app Stockscreener
20.65
4.93%
0.97
Dopo l'orario di chiusura:
20.80
0.15
+0.73%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
Takeda (TAK) Ends Collaboration on Drug Development with Denali Therapeutics - GuruFocus
SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics Inc. $DNLI Stake Increased by Aberdeen Group plc - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
DNLI Technical Analysis & Stock Price Forecast - Intellectia AI
Denali Therapeutics Inc. (DNLI) stock price, news, quote and history - Yahoo Finance Singapore
Denali Regains DNL593 Rights After Takeda Collaboration Ends - TipRanks
Denali Therapeutics Regains Full Rights to DNL593 as Takeda Ends 2018 Collaboration - TradingView
Denali Therapeutics Inc. And Takeda Terminate Collaboration Agreement For DNL593 - marketscreener.com
Takeda exits DNL593 deal; Denali (NASDAQ: DNLI) takes full control of FTD-GRN drug - Stock Titan
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) - The Manila Times
Takeda exits dementia drug pact, Denali targets trial data by 2026 end - Stock Titan
Aug Opening: Is Denali Therapeutics Inc a turnaround storyQuarterly Market Review & Community Verified Trade Alerts - baoquankhu1.vn
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes - BioSpace
Market Overview: Will Denali Therapeutics Inc outperform small cap indexesQuarterly Market Review & Weekly High Return Opportunities - baoquankhu1.vn
Pullback Watch: Will Denali Therapeutics Inc benefit from government policy2026 AllTime Highs & Capital Protection Trade Alerts - baoquankhu1.vn
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Benzinga
Denali Therapeutics Receives $200 Million Following FDA Accelerated Approval of Tividenofusp Alfa and Royalty Agreement Closing - minichart.com.sg
Denali Therapeutics scores $200 million shortly after first drug approval - The Business Journals
Denali Therapeutics Secures $200 Million Royalty Funding - TipRanks
Denali Therapeutics receives $200 million from royalty agreement after FDA approval - Investing.com India
Denali Therapeutics (NASDAQ: DNLI) closes $200M royalty deal after FDA OK - Stock Titan
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Sahm
Denali Therapeutics (DNLI) Is Down 13.9% After First BBB-Crossing Hunter Therapy Wins FDA NodWhat's Changed - Yahoo Finance
Is Denali Therapeutics’ (DNLI) First Brain-Penetrant Biologic Redefining Its Platform Value Proposition? - simplywall.st
(DNLI) Volatility Zones as Tactical Triggers - Stock Traders Daily
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter SyndromeSlideshow (NASDAQ:DNLI) 2026-03-27 - Seeking Alpha
Denali Therapeutics (DNLI): Goldman Sachs Raises Price Target to $40 | DNLI Stock News - GuruFocus
Stifel Nicolaus Issues Positive Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price - Defense World
Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $42.00 at HC Wainwright - Defense World
(DNLI.O) | Stock Price & Latest News - Reuters
FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs - MedCity News
Vanguard disaggregation: no beneficial DNLI shares reported (DNLI) - Stock Titan
Denali Receives FDA Approval for Hunter Syndrome Treatment, Shares Rise - Bitget
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up - Yahoo Finance
Morgan Stanley Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 5.7%Time to Sell? - MarketBeat
H.C. Wainwright raises Denali Therapeutics price target to $42 By Investing.com - Investing.com Australia
The Goldman Sachs Group Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
H.C. Wainwright raises Denali Therapeutics price target to $42 - Investing.com UK
Denali Therapeutics (DNLI) Receives Analyst Rating Update from B - GuruFocus
Robert W. Baird Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease - Benzinga
Some 13 years and $2 billion later, Denali Therapeutics wins first drug approvalSan Francisco Business Times - The Business Journals
Denali Delivers ‘Welcome Positive’ for Rare Disease Space With FDA's Hunter Syndrome Nod - BioSpace
FDA approves Denali’s Hunter syndrome brain therapy AVLAYAH By Investing.com - Investing.com Australia
FDA approves drug to treat neurologic manifestations of Hunter syndrome - The Pharma Letter
Denali gains on FDA approval of lead asset - MSN
Stifel raises Denali Therapeutics price target on drug approval By Investing.com - Investing.com Australia
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) - BioSpace
Goldman Sachs raises Denali Therapeutics stock price target on FDA approval - Investing.com Australia
Denali approval revives surrogate-endpoint path in neuronal MPS - BioCentury
Goldman Sachs raises Denali Therapeutics stock price target on FDA approval By Investing.com - za.investing.com
Stifel raises Denali Therapeutics price target on drug approval - Investing.com
Denali Therapeutics Wins FDA Accelerated Approval for AVLAYAH in Hunter Syndrome, Eyes Launch Boost - MarketBeat
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):